Quidelortho Corporation · NASDAQ:QDEL
Quidelortho — Q1 2026 Earnings Presentation
14 slides from Quidelortho's earnings presentation, May 5, 2026
Slide 1: QuidelOrtho First Quarter 2026 Financial Results
May 5, 2026 QuidelOrtho First Quarter 2026 Financial Results © 2026 QuidelOrtho Corporation. All rights reserved. | 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures
Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are
Slide 3: Basis of Presentation
Basis of Presentation • 2026 financials are as of the three months ended March 29, 2026 and 2025 financials are as of the three months ended March 30, 2025. • Revenue growth rates are shown on a constant currency basis unless otherwise noted. The term "constant currency" means we have translated loc
Slide 4: Q1 2026 Revenue Highlights
Q1 2026 Revenue Highlights Across Highly Across Key Healthcare Recurring Regions Settings Revenue $620M $620M $620M (13)% y/y (13)% y/y (13)% y/y Constant Currency Constant Currency Constant Currency Q1 2026 Financial Results Presentation | May 5, 2026 See Non-GAAP Financial Measures on slide 2, Bas
Slide 5: Q1 2026 Financial Results
Q1 2026 Financial Results Adj Operating Expenses Adj EBITDA Adj Diluted Loss Per Share Cash $227M $109M $(0.04) $140M Adj. EBITDA Margin Free Cash Flow (a) (2)% y/y 17.5% (105)% y/y $(67)M Total Net Debt SM&A Adj Gross Profit Margin Adj Tax Rate $2.6B $185M | 3% y/y 43.8% | (630) bps y/y 24.5% Net D
Slide 6: FY 2026 Financial Guidance
FY 2026 Financial Guidance • Considering first-quarter 2026 performance and current market dynamics in China, the Company has updated its previously provided financial guidance as of 5/5/26. This As of 5/5/26 guidance includes expected 2026 impact from the current draft of the China National Health
Slide 7: Appendix
Appendix © 2026 QuidelOrtho Corporation. All rights reserved. | 7
Slide 8: Non-GAAP Adjustments
Non-GAAP Adjustments Fiscal Quarter In millions Q1 2026 Q1 2025 Employee compensation charges $ 2.3 $ — Accelerated depreciation 2.0 — Incremental depreciation on PP&E fair value adjustment 1.8 3.3 Amortization of deferred cloud computing implementation costs 0.7 0.3 Other adjustments 0.6 — Cost of
Slide 9: Q1 2026 Non-GAAP Reconciliation
Q1 2026 Non-GAAP Reconciliation Fiscal Quarter Q1 2026 Fiscal Quarter Q1 2025 In millions GAAP Adjustments (1) Non-GAAP GAAP Adjustments (1) Non-GAAP Gross profit $ 263.8 $ 7.4 $ 271.2 $ 343.3 $ 3.6 $ 346.9 Selling, marketing and administrative 199.3 (14.5) 184.8 187.0 (6.8) 180.2 Research and devel
Slide 10: Revenue by Geography
Revenue by Geography Three Months Ended In millions 2025 2026 First Quarter Q1 Q2 Q3 Q4 Q1 Percent Currency Constant Change Impact Currency (1) North America $406.7 $310.7 $381.4 $390.1 $328.9 (19.1)% (0.2)% (18.9)% EMEA 88.9 87.3 91.8 92.7 92.5 4.0% 10.1% (6.1)% China 75.0 83.4 84.6 91.7 63.5 (15.3
Slide 11: Revenue by Business Unit
Revenue by Business Unit Three Months Ended In millions 2025 2026 First Quarter Q1 Q2 Q3 Q4 Q1 Percent Currency Constant Change Impact Currency (1) Labs $373.0 $369.7 $373.8 $389.2 $353.1 (5.3)% 2.3% (7.6)% Immunohematology 128.5 132.3 142.0 141.0 138.3 7.6% 4.2% 3.4% Donor Screening 12.8 13.3 14.7
Slide 12: Revenue by Respiratory and Non-Respiratory
Revenue by Respiratory and Non-Respiratory Three Months Ended In millions 2025 2026 First Quarter Q1 Q2 Q3 Q4 Q1 Percent Currency Constant Change Impact Currency (1) Respiratory Revenue $119.8 $46.7 $112.3 $123.3 $67.9 (43.3)% 0.3% (43.6)% Non-Respiratory Revenue 573.0 567.2 587.6 600.3 551.9 (3.7)%
Slide 13: Non-GAAP Reconciliations – Adjusted EBITDA
Non-GAAP Reconciliations – Adjusted EBITDA Fiscal Quarter In millions Q1 2026 Q1 2025 Net loss $ (91.8) $ (12.7) Depreciation and amortization 112.9 107.1 Interest expense, net 51.1 40.0 Provision for income taxes 12.3 3.9 Restructuring, integration and other charges 4.4 16.1 Amortization of deferre
Slide 14: quidelortho.com
Lt SIMIC ENO Tey quidelortho.co